Form 4: ARS Pharmaceuticals Director Brent Saunders Executes Stock Option and Sells Shares

Director Brent Saunders exercised stock options and sold 120,000 shares of ARS Pharmaceuticals, Inc. on May 20, 2025.

Summary

• On May 20, 2025, Brent L Saunders, a director of ARS Pharmaceuticals, Inc. (SPRY), exercised stock options to acquire 120,000 shares of common stock at a price of $1.01 per share.
• Simultaneously, Saunders sold 120,000 shares of common stock at a weighted average price of $14.2502, with prices ranging from $14.25 to $14.26.
• Following these transactions, Saunders directly owns 470,950 derivative securities.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of insider trading activity. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, providing transparency to the market regarding the actions of company directors. It's common for executives to exercise stock options and sell shares for personal financial management.

Stakeholder Impact

• The sale of shares by a director could be perceived negatively by some shareholders, but it's a common practice and doesn't necessarily reflect a lack of confidence in the company.

Key Dates

Keywords

ARS Pharmaceuticals, SPRY, Brent Saunders, Stock Options, SEC Form 4, Director, Share Sale, Beneficial Ownership